Risdiplam

Phase 3

Roche Holding AG (RHHBY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Oct '26

RHHBYPhase 3$316.4B

Risdiplam Phase 3 Est. Readout

Risdiplam• Muscular Atrophy, Spinal259

Oct 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Muscular Atrophy, Spinal

View Full Landscape

Drug Information

Target Indication

Muscular Atrophy, Spinal

Clinical Trial

NCT05808764

Last updated: 1/21/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA3/26/2021

Evrysdi

Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.

AcceleratedPRIME

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

RHHBY

Roche Holding AG

Biotechnology•Europe•NYSE

Related Pipeline

RO7204239Phase 3

Obesity

trastuzumab (Herceptin®)Phase 3

Breast Cancer

mycophenolate mofetil [CellCept]Phase 3

Myasthenia Gravis Generalised

LenvatinibPhase 3

Unresectable Hepatocellular Carcinoma

RO7239361Phase 3

Duchenne Muscular Dystrophy

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts